Compare RHP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHP | NUVL |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 7.1B |
| IPO Year | 1991 | 2021 |
| Metric | RHP | NUVL |
|---|---|---|
| Price | $94.84 | $106.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 15 |
| Target Price | $109.33 | ★ $135.00 |
| AVG Volume (30 Days) | 443.6K | ★ 557.9K |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 5.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.77 | N/A |
| Revenue | ★ $2,486,871,000.00 | N/A |
| Revenue This Year | $8.66 | N/A |
| Revenue Next Year | $7.67 | N/A |
| P/E Ratio | $25.39 | ★ N/A |
| Revenue Growth | ★ 6.48 | N/A |
| 52 Week Low | $76.27 | $55.54 |
| 52 Week High | $108.42 | $113.02 |
| Indicator | RHP | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 52.77 |
| Support Level | $94.44 | $105.05 |
| Resistance Level | $98.34 | $113.02 |
| Average True Range (ATR) | 2.17 | 5.29 |
| MACD | 0.08 | 0.35 |
| Stochastic Oscillator | 55.61 | 58.21 |
Ryman Hospitality Properties Inc is a lodging and hospitality real estate investment trust that specializes in upscale convention center resorts and country music entertainment experiences. Its core holdings are Gaylord Opryland Resort & Convention Center; Gaylord Palms Resort & Convention Center; Gaylord Texan Resort & Convention Center; Gaylord National Resort & Convention Center; and Gaylord Rockies Resort & Convention Center. The company has three business segments: Hospitality, which includes Gaylord Hotels properties, the Inn at Opryland, and the AC Hotel, Entertainment which includes the entertainment and media assets comprising OEG, and Corporate and Other, which includes corporate expenses. It derives the vast majority of its revenue from its Hospitality segment.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.